MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.080
+0.150
+5.12%
Pre Market: 3.080 0 0.00% 05:26 03/04 EST
OPEN
2.980
PREV CLOSE
2.930
HIGH
3.140
LOW
2.880
VOLUME
199
TURNOVER
--
52 WEEK HIGH
8.59
52 WEEK LOW
1.250
MARKET CAP
61.86M
P/E (TTM)
-1.4384
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Business Wire · 1d ago
NIU, SPPI, BDSI and SVC among after-hours movers
Gainers: [[SIOX]] +12.1%. [[OPTN]] +7.2%. [[BDSI]] +5.7%. [[SSP]] +4.9%. [[SPPI]] +4.9%.Losers: [[PCTI]] -6.5%. [[SVC]] -5.4%. [[GNFT]] -4.2%. [[NIU]] -3.4% [[CATB]] -2%.
Seekingalpha · 5d ago
3 Biotech Penny Stocks to Watch as February Approaches
Feb 24, 2021 (Penny Stocks via COMTEX) -- Will These Biotech Penny Stocks Continue to Make Moves Next Month? With February right around the corner, we see...
Penny Stocks · 02/24 21:10
Viela Bio, Dynavax Technologies leads healthcare gainers; Matinas BioPharma, Concert Pharmaceuticals among major losers
Gainers: Viela Bio (VIE) +53%, Dynavax Technologies (DVAX) +36%, Applied Therapeutics (APLT) +29%, BioCryst Pharmaceuticals (BCRX) +28%, Vaxart (VXRT) +26%.Losers: Matinas BioPharma (MTNB) -33%, Concert Pharmaceuticals (CNCE) -31%, Catabasis Pharmaceutical...
Seekingalpha · 02/01 16:03
DD, CNCE among premarket losers
Concert Pharmaceuticals (CNCE) -47% after CTP-692 study in schizophrenia fails to meet primary or secondary endpoint.Universal Security Instruments (UUU) -18%.Quotient (QTNT) -15% despite FQ3 beat.Yield10 Bioscience (YTEN) -14% after pricing share offering...
Seekingalpha · 02/01 13:29
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Catabasis Pharmaceuticals (CATB) and Cullinan Management (CGEM)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catabasis Pharmaceuticals (CATB) and Cullinan Management (CGEM).
SmarterAnalyst · 02/01 11:15
MSTR, ZI, ADMS and CATB among after-hours movers
 Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%.
Seekingalpha · 01/29 22:45
Mid-Afternoon Market Update: Dow Tumbles 450 Points; Catabasis Pharmaceuticals Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 1.47% to 30,153.13 while the NASDAQ fell 1.56% to 13,129.54. The S&P also fell, dropping 1.43% to 3,733.22.
Benzinga · 01/29 20:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CATB. Analyze the recent business situations of Catabasis Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CATB stock price target is 24.00 with a high estimate of 24.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 9.68M
% Owned: 48.18%
Shares Outstanding: 20.08M
TypeInstitutionsShares
Increased
16
976.04K
New
39
-1.75M
Decreased
14
524.91K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Senior Vice President/General Counsel
Benjamin Harshbarger
Chief Scientific Officer
Andrew Nichols
Other
Edward Hibben
Other
Joanne Donovan
Other
Andrew Komjathy
Director
Fred Callori
Director
Jonathan Violin
Independent Director
Burt Adelman
Independent Director
Joanne Beck
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
  • Dividends
  • Splits
  • Insider Activity
No Data
About CATB
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Webull offers kinds of Catabasis Pharmaceuticals Inc stock information, including NASDAQ:CATB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CATB stock methods without spending real money on the virtual paper trading platform.